Inventor · disambiguated record
Claudio Sustmann
Also filed as: SUSTMANN CLAUDIO
12 granted patents·17 pending applications·57 citations·filing 2010–2020
88Inventor score
Top patents by PatentIndex Score
29 records- 0194US9890204B2Trivalent, bispecific antibodiesBRINKMANN ULRICH·Filed 2012·Granted Feb 13, 2018·27 cites·11 claims
- 0291US10611825B2Monovalent antigen binding proteinsHOFFMANN LA ROCHE·Filed 2017·Granted Apr 7, 2020·6 cites·8 claims
- 0391US9982036B2Dual FC antigen binding proteinsBOSSENMAIER BIRGIT·Filed 2012·Granted May 29, 2018·12 cites·3 claims
- 0489US11732052B2Bispecific antibody molecules with antigen-transfected T-cells and their use in medicineHOFFMANN LA ROCHE·Filed 2020·Granted Aug 22, 2023·3 cites·19 claims
- 0587US10434184B2Anti-TPBG antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Oct 8, 2019·3 cites·22 claims
- 0680US10633451B2Bispecific antibody molecules with antigen-transfected T-cells and their use in medicineHOFFMANN LA ROCHE·Filed 2013·Granted Apr 28, 2020·4 cites·16 claims
- 0778US10584178B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 10, 2020·2 cites·6 claims
- 0870US11993642B2Trivalent, bispecific antibodiesHOFFMANN LA ROCHE·Filed 2019·Granted May 28, 2024·0 cites·10 claims
- 0963US11787873B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·0 cites·17 claims
- 1062US10793621B2Nucleic acid encoding dual Fc antigen binding proteinsHOFFMANN LA ROCHE·Filed 2018·Granted Oct 6, 2020·0 cites·5 claims
- 1162US2013156772A1Bispecific Anti ErbB1 / Anti cMet AntibodiesROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 1262US2013273054A1Bispecific Anti ErbB2/Anti cMet AntibodiesROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 1360US2022017640A1Activatable bispecific antibodiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 1459US2018282399A1Trivalent, bispecific antibodiesHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 1556US2020108154A1Anti-tpbg antibodies and methods of useHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 1655US2014135482A1Bispecific Anti ErbB3 / Anti cMet AntibodiesROCHE GLYCART AG·Filed 2014·Application pending·0 cites
- 1754US2010254988A1Bispecific Anti ErbB2 / Anti cMet AntibodiesBOSSENMAIER BIRGIT·Filed 2010·Application pending·0 cites
- 1854US2010254989A1Bispecific Anti ErbB1 / Anti c Met AntibodiesBOSSENMAIER BIRGIT·Filed 2010·Application pending·0 cites
- 1953US2013288267A1Detection of a polypeptide dimer by a bivalent binding agentROCHE DIAGNOSTICS OPERATIONS·Filed 2013·Application pending·0 cites
- 2051US2010256340A1Trivalent, bispecific antibodiesBRINKMANN ULRICH·Filed 2010·Application pending·0 cites
- 2149US10808038B2HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2HOFFMANN LA ROCHE·Filed 2016·Granted Oct 20, 2020·0 cites·6 claims
- 2249US2017275380A1Detection of a polypeptide dimer by a bivalent binding agentROCHE DIAGNOSTICS OPERATIONS INC·Filed 2017·Application pending·0 cites
- 2349US2012237507A1Monovalent Antigen Binding ProteinsBOSSENMAIER BIRGIT·Filed 2012·Application pending·0 cites
- 2449US2013266568A1Activatable bispecific antibodiesROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2546US2017198043A1Bispecific antigen binding moleculesROCHE GLYCART AG·Filed 2016·Application pending·0 cites
- 2644US2015166670A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 2744US2010256339A1Bispecific Anti ErbB3 / Anti cMet AntibodiesBOSSENMAIER BIRGIT·Filed 2010·Application pending·0 cites
- 2843US2013058937A1Bispecific antigen binding moleculesAUER JOHANNES·Filed 2012·Application pending·0 cites
- 2939US11547748B2Adoptive t-cell therapyHOFFMANN LA ROCHE·Filed 2017·Granted Jan 10, 2023·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when Claudio Sustmann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →